Science 37 to merge with LifeScience Acquisition II

By Jenni Spinner contact

- Last updated on GMT

(mikdam/iStock via Getty Images Plus)
(mikdam/iStock via Getty Images Plus)

Related tags: Science 37, Decentralized trials, Mergers and acquisitions

The newly formed company (valued at $1.05b USD) will center on funding the firm’s decentralized trial technology platform and exploring new opportunities,

Science 37, developer of the Decentralized Clinical Trial Operating System, has announced it has entered into a definitive business combination agreement with LifeSci Acquisition II, a ‘blank check’ investment outfit focused on pharmaceutical, medical technology, digital health, and healthcare services sectors. After the deal completes, the new company, which is valued at approximately $1.05b USD, will operate as Science 37.

According to Science 37 CEO David Coman, the move comes at a time of rapid, significant innovation in the clinical trial field.

The clinical research industry is undergoing a dramatic transformation in which traditional development methods are being supplanted by technology-fueled innovation​,” Coman said. “Our clinical trial operating system (OS) can enable significantly faster enrollment, retain patients at a meaningfully higher rate, and achieve higher enrollment among diverse patient populations; with this investment, we expect to advance our OS to further penetrate adjacent markets, and power the future of clinical research where we bridge between the traditional and decentralized approaches to enable a truly agile clinical tria​l.”

Since Science 37’s founding in 2014, the company reportedly has conducted more than 95 decentralized clinical trials, engaging in excess of 366,000 patient participants. According to the firm, it has been effective in demonstrating an ability to accelerate patient enrollment, improve participant retention, and connect with a more diverse, inclusive population.

Andrew McDonald, CEO of LifeSci Acquisition II, said the surge in interest in and adoption of the virtual study format puts Science 37 in prime territory.

Healthcare is increasingly transitioning to virtual and home-based environments, and we believe Science 37 is uniquely positioned as a pioneer in its approach to clinical trials​," McDonald said. "The company’s rapid growth is a testament to its truly disruptive technology and its immense market opportunity to change the way drugs are developed and go to market​.”

Over the course of the past year, Science 37 has forged partnerships with a number of other industry companies:

Related news

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us

Products

View more

Webinars